Cytogen
Biotechnology company that develops and sells CTC enrichment systems for cancer diagnosis and treatment in South Korea.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
CytoGen, Inc. operates in the biotechnology sector, focusing on the development and application of liquid biopsy technology to improve cancer treatment. The company's core product is its Liquid Biopsy Platform, which utilizes Circulating Tumor Cells (CTCs) to identify genetic mutations in cancer patients. This technology allows for the isolation and molecular characterization of viable CTCs, including RNA, DNA, and protein levels, as well as CTC cultures. By providing detailed genetic information, CytoGen's platform aids in the application of personalized medicine, offering tailored treatment plans for cancer patients.
CytoGen serves a diverse range of clients, including pharmaceutical companies, research institutions, and clinical laboratories. The company operates in the global healthcare market, with a particular focus on oncology. Its business model revolves around collaborative partnerships and the provision of specialized diagnostic services. Revenue is generated through service contracts, collaborative research agreements, and the sale of diagnostic kits and devices.
CytoGen's technology is distinguished by its ability to isolate viable CTCs, which are released from primary tumors and disseminate through the bloodstream, often leading to metastasis and poor clinical outcomes. The platform's expandability allows for various applications, including biomarker discovery, clinical research, and personalized treatment planning.
Keywords: Liquid biopsy, Circulating Tumor Cells, personalized medicine, cancer treatment, molecular characterization, biotechnology, oncology, diagnostic services, collaborative research, genetic mutations.
